Dompe Signs Up First Patient for Reparixin Phase III Trial

Italy’s Dompe have confirmed that they have signed up their first patient onto a late-stage clinical trial evaluating reparixin as a possible treatment for type 1 diabetes. The compound, a selective chemokine interleukin-8 inhibitor, has been shown to increase the efficacy of transplantation of insulin-producing pancreatic islets, which the company commented is “the new frontier

Continue Reading